ZIOP ZIOPHARM Oncology, Inc. Stock Quote

ZIOP [NASD]

Index	-	P/E	-	EPS (ttm)	-0.38	Insider Own	2.20%	Shs Outstand	213.03M	Perf Week	0.30%
Market Cap	737.10M	Forward P/E	-	EPS next Y	-0.47	Insider Trans	-3.94%	Shs Float	200.43M	Perf Month	-20.71%
Income	-80.00M	PEG	-	EPS next Q	-0.10	Inst Own	57.00%	Short Float	19.65%	Perf Quarter	-5.13%
Sales	-	P/S	-	EPS this Y	45.60%	Inst Trans	0.79%	Short Ratio	14.44	Perf Half Y	23.79%
Book/sh	0.58	P/B	5.74	EPS next Y	-6.80%	ROA	-46.20%	Target Price	5.67	Perf Year	24.72%
Cash/sh	0.52	P/C	6.40	EPS next 5Y	-	ROE	-52.20%	52W Range	2.06 - 5.95	Perf YTD	32.14%
Dividend	-	P/FCF	-	EPS past 5Y	16.80%	ROI	-	52W High	-47.06%	Beta	2.07
Dividend %	-	Quick Ratio	7.10	Sales past 5Y	-	Gross Margin	-	52W Low	52.91%	ATR	0.26
Employees	103	Current Ratio	7.10	Sales Q/Q	-	Oper. Margin	-	RSI (14)	35.33	Volatility	6.72% 7.03%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-22.00%	Profit Margin	-	Rel Volume	0.45	Prev Close	3.33
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Feb 25 AMC	Payout	-	Avg Volume	2.73M	Price	3.15
Recom	2.60	SMA20	-10.77%	SMA50	-26.56%	SMA200	-2.92%	Volume	1,049,625	Change	-5.41%

Mar-12-21

Downgrade

Jefferies

Buy → Hold

$7 → $5

Mar-01-21

Downgrade

H.C. Wainwright

Buy → Neutral

Jun-19-20

Initiated

Jefferies

Buy

Mar-04-20

Initiated

Cantor Fitzgerald

Overweight

Aug-23-19

Resumed

Raymond James

Outperform

Apr-04-19

Initiated

Lake Street

Buy

Apr-01-19

Initiated

Laidlaw

Buy

$7.50

Nov-15-18

Upgrade

Raymond James

Mkt Perform → Outperform

Jun-18-18

Downgrade

JP Morgan

Neutral → Underweight

Jun-01-17

Initiated

H.C. Wainwright

Buy

$9.50

Aug-10-16

Upgrade

Wells Fargo

Underperform → Market Perform

Jul-19-16

Reiterated

Mizuho

Neutral

$7 → $5

Jun-02-16

Initiated

Raymond James

Mkt Perform

May-11-16

Reiterated

Mizuho

Neutral

$6 → $7

Jan-25-16

Reiterated

Mizuho

Neutral

$10 → $6

Dec-04-15

Initiated

Wells Fargo

Underperform

Jun-10-15

Reiterated

Mizuho

Neutral

$14 → $10

Mar-10-15

Downgrade

Mizuho

Buy → Neutral

$14

Mar-02-15

Reiterated

Mizuho

Buy

$11 → $14

Mar-20-14

Initiated

Mizuho

Buy

$11

Apr-19-21 08:00AM	Ziopharm Oncology Announces First Patient Infused in CD19 RPM CAR-T Phase I Clinical Trial Being Conducted by Joint Venture Partner Eden BioCell GlobeNewswire -5.41%
Apr-07-21 09:00AM	Ziopharm Oncology to Present Poster at American Association for Cancer Research Virtual 2021 Annual Meeting GlobeNewswire
Mar-23-21 10:19AM	What Type Of Shareholders Make Up ZIOPHARM Oncology, Inc.'s (NASDAQ:ZIOP) Share Registry? Simply Wall St. -7.64%
Mar-12-21 11:43AM	Why Ziopharm Oncology Stock Is Sinking Today Motley Fool -8.92%
Feb-26-21 12:22PM	Why Ziopharm Oncology Stock Is Jumping Today Motley Fool +14.62%
09:30AM	Ziopharm Oncology Inc (ZIOP) Q4 2020 Earnings Call Transcript Motley Fool
Feb-25-21 04:05PM	Ziopharm Oncology Provides Leadership and Corporate Updates; Reports Fourth Quarter and Full Year 2020 Financial Results GlobeNewswire -5.10%
02:30PM	ZIOPHARM Oncology, Inc. to Host Earnings Call ACCESSWIRE
Feb-16-21 04:01PM	Ziopharm Oncology to Report Fourth Quarter and Full Year 2020 Financial Results and Host Webcast on February 25, 2021 GlobeNewswire
Feb-08-21 09:55AM	Analyzing ZIOPHARM Oncology's Unusual Options Activity Benzinga +6.67%
Feb-05-21 12:00PM	Why Ziopharm Oncology Stock Is Soaring Today Motley Fool +19.05%
09:00AM	Ziopharm Oncology Announces Election of Robert Postma to its Board of Directors GlobeNewswire
Jan-14-21 08:00AM	Ziopharm Oncology Announces Election of James Huang as Chairman of the Board of Directors GlobeNewswire +15.46%
Dec-23-20 04:01PM	Ziopharm to Participate in Upcoming January Conferences GlobeNewswire
05:14AM	Companies Like ZIOPHARM Oncology (NASDAQ:ZIOP) Are In A Position To Invest In Growth Simply Wall St.
Dec-22-20 07:45AM	The Daily Biotech Pulse: Ziopharm To Start Blood Cancer Study, Chemocentryx & Soligenix Slump On Adverse Clinical Trial Outcomes Benzinga +5.00%
Dec-21-20 04:01PM	Ziopharm Oncology Announces Clearance of Taiwans First IND of Non-viral CAR-T for the Treatment of Relapsed CD19+ Leukemias and Lymphomas GlobeNewswire
Dec-17-20 09:00AM	WaterMill Asset Management Issues Statement Regarding Consent Solicitation at Ziopharm Oncology Business Wire +7.61%
08:56AM	Are Options Traders Betting on a Big Move in Ziopharm (ZIOP) Stock? Zacks
Dec-16-20 04:01PM	Ziopharm Comments on Consent Solicitation Results GlobeNewswire
Dec-15-20 07:52AM	The Daily Biotech Pulse: Mesoblast Releases Mixed Data, MediWound Jumps On Distribution Deal, Kezar Life Sciences Rallies On Index Inclusion, Opiant Gets BARA Funding Benzinga -8.41%
Dec-14-20 04:02PM	Ziopharm Oncology Announces Chief Financial Officer to Step Down GlobeNewswire +11.55%
12:06AM	Is ZIOP A Good Stock To Buy Now? Insider Monkey
Dec-12-20 05:15PM	WaterMill Asset Management Addresses Ziopharm Oncologys Latest Distortion and Recent Threat Business Wire
Dec-11-20 06:57PM	Ziopharm Comments on Delay of WaterMills Stated Consent Deadline GlobeNewswire
Dec-10-20 07:01PM	Egan-Jones Recommends Against Electing Dissidents Full Slate of Nominees to Ziopharm Board GlobeNewswire
Dec-08-20 09:00AM	WaterMill Asset Management Reinforces the Need for Meaningful and Urgent Change at Ziopharm Oncology Business Wire +5.86%
Dec-04-20 08:30AM	Ziopharm Details Actions in Response to Shareholder Feedback GlobeNewswire
Dec-02-20 10:04PM	Proxy firm Glass Lewis backs investor WaterMill's board nominees at Ziopharm Oncology Reuters
09:00PM	Glass Lewis Recommends Ziopharm Shareholders Vote on the WHITE Consent Card for All of WaterMills Director Candidates and Proposals Business Wire
Nov-28-20 05:30PM	WaterMill Asset Management Refutes Ziopharm Oncologys Desperate, Low-Road Smear Campaign Business Wire
Nov-27-20 05:32PM	Ziopharm Comments on Institutional Shareholder Services Recommendation to Reject WaterMills Attempt to Remove Half of Ziopharms Board of Directors GlobeNewswire
Nov-25-20 08:30PM	ISS Recommends Ziopharm Shareholders Vote for Change on WaterMill Asset Managements WHITE Consent Card Business Wire
07:36PM	ISS backs two of three of activist's board nominees at Ziopharm Oncology Reuters
Nov-24-20 09:00AM	WaterMill Asset Management Sets the Record Straight Following Ziopharms Apparent Attempt to Mislead Shareholders and Rewrite History Business Wire
Nov-20-20 11:00AM	Ziopharm Releases Investor Presentation Highlighting Execution of Strategy and Substantial Board Refreshment to Enhance Shareholder Value GlobeNewswire
Nov-19-20 09:30AM	WaterMill Asset Management Releases Presentation Detailing the Case for Urgent Change Atop Ziopharm Oncology Business Wire
09:00AM	Ziopharm Oncology Presents Encouraging Clinical Data for Controlled IL-12 for the Treatment of Glioblastoma and DIPG at the 2020 Society for Neuro-Oncology Annual Meeting GlobeNewswire
09:00AM	White Rock Capital Supports WaterMill's Case for Change at Ziopharm Oncology PR Newswire
Nov-17-20 04:15PM	Ziopharm Oncology Appoints Raffaele Baffa, M.D., Ph.D., as Chief Medical Officer GlobeNewswire
Nov-16-20 08:30AM	Ziopharm Oncology Appoints Mary Thistle to Board of Directors GlobeNewswire
Nov-13-20 09:15AM	Ziopharm Oncology to Participate in Jefferies Virtual London Healthcare Conference on November 19, 2020 GlobeNewswire
Nov-12-20 09:00AM	WaterMill Asset Management Releases Candid Q&As with Each of its Director Candidates for Election to Ziopharm Oncologys Board Business Wire
Nov-06-20 10:31PM	Ziopharm Oncology Inc (ZIOP) Q3 2020 Earnings Call Transcript Motley Fool -7.44%
Nov-05-20 04:02PM	Ziopharm Oncology Reports Third Quarter 2020 Financial Results and Provides Corporate Update GlobeNewswire
02:30PM	ZIOPHARM Oncology, Inc. to Host Earnings Call ACCESSWIRE
09:05AM	WaterMill Asset Management Sends Letter to Ziopharm Oncology Shareholders Business Wire
Nov-02-20 09:00AM	Ziopharm Files Definitive Consent Revocation Statement and Sends Letter to Shareholders GlobeNewswire +8.13%
08:45AM	WaterMill Asset Management Launches Consent Solicitation to Reconstitute the Board of Directors of Ziopharm Oncology Business Wire
08:00AM	REFILE-Ziopharm Oncology rebuffs investor's call for board seats Reuters
Oct-29-20 09:00AM	Ziopharm Oncology to Report Third Quarter 2020 Financial Results and Host a Conference Call and Webcast on November 5, 2020 GlobeNewswire
Oct-16-20 04:00PM	Ziopharm Oncology Announces Receipt of Shareholders Intent to Solicit Written Consents GlobeNewswire
Sep-30-20 06:26PM	Penny Stocks to Buy Using Technical Analysis for October 2020 Investopedia
Sep-23-20 01:48PM	Is ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Popular Amongst Institutions? Simply Wall St. -6.44%
Sep-22-20 08:30AM	Ziopharm Oncology Appoints Kevin Buchi to its Board of Directors GlobeNewswire
Sep-15-20 08:30AM	Ziopharm Oncology Appoints Four Additional Members to Scientific Advisory Board GlobeNewswire +5.73%
Sep-14-20 04:17PM	Why Ziopharm Oncology Shares Zoomed Higher Today Motley Fool +12.50%
08:30AM	Ziopharm Oncology Granted Rare Pediatric Disease Designation for Controlled IL-12 for the Treatment of DIPG GlobeNewswire
Sep-10-20 09:00AM	Ziopharm Oncology to Participate in Upcoming Conferences GlobeNewswire
Sep-07-20 09:58AM	ZIOPHARM Oncology (ZIOP) Has Fallen 47% in Last One Year, Underperforms Market Insider Monkey
Aug-06-20 04:04PM	Ziopharm Oncology Reports Second Quarter 2020 Financial Results and Provides Corporate Update GlobeNewswire
Jul-28-20 09:00AM	Ziopharm Oncology to Report Second Quarter 2020 Financial Results and Host a Conference Call and Webcast on August 6, 2020 GlobeNewswire -5.33%
Jul-22-20 08:30AM	Ziopharm Oncology Names James Huang to Board of Directors GlobeNewswire
Jul-10-20 07:25AM	The Daily Biotech Pulse: Ziopharm Starts Blood Cancer Study, Allergan's Botox Gets Label Expansion, 3 IPOs Benzinga
Jul-09-20 04:15PM	Ziopharm Oncology Announces Initiation of Phase 1 Trial Evaluating Rapid Personalized Manufacturing CAR-T Technology in Patients with Relapsed CD19+ Leukemias and Lymphomas GlobeNewswire
Jul-08-20 08:30AM	Ziopharm Oncology Doses First DIPG Patient in Phase 1/2 Trial of Controlled IL-12 for the Treatment of Pediatric Brain Tumors GlobeNewswire
Jun-30-20 11:47PM	ZIOPHARM Oncology Inc. (ZIOP): Are Hedge Funds Right About This Stock? Insider Monkey
Jun-22-20 09:48AM	Analysts: These 3 Penny Stocks May Very Well Be Worth the Risk TipRanks +8.56%
08:00AM	Ziopharm Oncology Completes Enrollment of Phase 2 Trial Evaluating Controlled IL-12 in Combination with Libtayo® in Patients with Glioblastoma GlobeNewswire
Jun-15-20 08:33AM	Do Options Traders Know Something About Ziopharm Oncology (ZIOP) Stock We Don't? Zacks +9.18%
08:00AM	Ziopharm Oncology Appoints Carl June, M.D., as Chairman of Scientific Advisory Board GlobeNewswire
Jun-12-20 09:00AM	Ziopharm Oncology to Participate in Cell Therapy Panel at the Raymond James Human Healthcare Innovation Conference on June 17, 2020 GlobeNewswire
06:09AM	Edited Transcript of ZIOP earnings conference call or presentation 7-May-20 8:30pm GMT Thomson Reuters StreetEvents
May-29-20 08:00AM	Ziopharm Oncology Presents Encouraging Clinical Data for Controlled IL-12 for the Treatment of Recurrent Glioblastoma at the 2020 American Society of Clinical Oncology GlobeNewswire
May-27-20 04:15PM	Ziopharm Oncology Announces Management Transition GlobeNewswire +7.06%
08:30AM	Ziopharm Oncology to Present at the Jefferies 2020 Healthcare Conference on June 3, 2020 GlobeNewswire
May-11-20 02:50PM	Here's Why We're Not Too Worried About ZIOPHARM Oncology's (NASDAQ:ZIOP) Cash Burn Situation Simply Wall St.
May-08-20 04:00PM	Ziopharm Oncology Inc (ZIOP) Q1 2020 Earnings Call Transcript Motley Fool
09:00AM	Ziopharm Oncology to Present at the BofA Securities 2020 Health Care Conference GlobeNewswire
May-07-20 04:05PM	Ziopharm Oncology Reports First Quarter 2020 Financial Results and Provides Corporate Update GlobeNewswire
Apr-30-20 08:00AM	Ziopharm Oncology Announces Poster Presentations at the 2020 American Society of Clinical Oncology Virtual Meeting GlobeNewswire -8.20%
Apr-27-20 08:30AM	Ziopharm Oncology to Report First Quarter 2020 Financial Results and Host a Conference Call and Webcast on May 7, 2020 GlobeNewswire +6.51%
Apr-06-20 06:00AM	Ziopharm- Catalysts in T-Cell Therapy MoneyShow +14.47%
Mar-04-20 12:37PM	Edited Transcript of ZIOP earnings conference call or presentation 2-Mar-20 9:30pm GMT Thomson Reuters StreetEvents +8.97%
Mar-02-20 04:05PM	Ziopharm Oncology Reports Financial Results for Fourth Quarter and Full Year 2019 GlobeNewswire
Feb-28-20 08:30AM	Ziopharm Oncology Presentation at the Barclays Global Healthcare Conference to be Webcast GlobeNewswire
Feb-24-20 08:30AM	Ziopharm Oncology to Host Conference Call to Discuss Fourth Quarter and Full Year 2019 Results on March 2, 2020 GlobeNewswire -5.76%
Feb-05-20 09:03AM	Ziopharm Oncology Announces Pricing of Public Offering of Common Stock GlobeNewswire -16.46%
07:43AM	The Daily Biotech Pulse: Merck Spins Off Slow-Growth Businesses, ZioPharm Announces Offering, PhaseBio Data Benzinga
Feb-04-20 04:01PM	Ziopharm Oncology Announces Proposed Public Offering of Common Stock GlobeNewswire
Jan-30-20 08:45AM	Ziopharm Oncology Announces Recent Publications in Peer-Reviewed Scientific Journals GlobeNewswire
Dec-30-19 08:56AM	Options Traders Expect Huge Moves in ZIOPHARM Oncology (ZIOP) Stock Zacks -6.99%
Dec-19-19 08:45AM	Ziopharm Oncology Presentation at the 38th Annual J.P. Morgan Healthcare Conference to be Webcast GlobeNewswire
Dec-11-19 11:23AM	Hedge Funds Have Never Been This Bullish On ZIOPHARM Oncology Inc. (ZIOP) Insider Monkey
Dec-09-19 05:00PM	Ziopharm Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Dec-08-19 09:00AM	Ziopharm Oncology Presents Pre-Clinical Data Validating Rapid Personalized Manufacture (RPM) with TCR at the 2019 American Society for Hematology Annual Meeting GlobeNewswire
Dec-06-19 08:00AM	12 Biotech Stocks Primed For A Short Squeeze Benzinga
Nov-23-19 09:00AM	Ziopharm Oncology Presents Encouraging Clinical Data for Controlled IL-12 for the Treatment of Recurrent Glioblastoma at the 2019 Society for Neuro-Oncology Annual Meeting GlobeNewswire
Nov-19-19 03:31PM	Edited Transcript of ZIOP earnings conference call or presentation 7-Nov-19 9:30pm GMT Thomson Reuters StreetEvents
Nov-18-19 07:00AM	Ziopharm Oncology Updates Presentation and Webcast Time at the Jefferies 2019 London Healthcare Conference GlobeNewswire

ZIOPHARM Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing a portfolio of immuno-oncology therapies to treat patients with cancer. The company develops Sleeping Beauty platform, which is based on the non-viral genetic engineering of immune cells using a transposon/transposase system to engineer T-cells outside of the body for infusion; and Controlled IL-12 to stimulate expression of interleukin 12 or IL-12, a master regular of the immune system, in a controlled manner to focus the patient's immune system to attack cancer cells. Its product candidates include T cell receptor + T therapies to target solid tumors; chimeric antigen receptor + T cell therapies targeting CD19 for hematologic malignancies; and Ad-RTS-hIL-12 plus veledimex, a gene delivery system to regulate production of IL-12 to treat patients with recurrent glioblastoma multiforme in adults. The company has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; a patent license agreement with the National Cancer Institute; and a cooperative research and development agreement with the National Cancer Institute. ZIOPHARM Oncology, Inc. is headquartered in Boston, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Buck Jill	EVP, GM Gene Therapy	Jan 08	Sale	3.12	27,894	87,029	199,516	Jan 12 04:35 PM
Lafond Kevin G	SVP, Treasurer & CAO	Jan 08	Sale	3.09	18,020	55,682	63,965	Jan 12 04:34 PM
Hadfield Robert	General Counsel and Secretary	Jan 08	Sale	3.12	26,500	82,680	133,319	Jan 12 04:33 PM
De Groot Eleanor	EVP, GM Cell Therapy	Jan 04	Sale	2.72	21,620	58,806	206,413	Jan 06 05:03 PM
Cooper Laurence James Neil	President and CEO	Jan 04	Sale	2.71	105,693	286,428	1,799,280	Jan 06 05:02 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience